Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 6/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.37 |
| ▸ | JUN | P05412 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | LATS1 | O95835 | 1/20 | 0.31 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.31 |
| ▸ | XPO1 | O14980 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.30 |
| ▸ | MERTK | Q12866 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20329968 | 0.84 | SYK (0.46) | JUNNFKB1NFKB2RELAKMT2A | |
| SCHEMBL30736504 | 0.84 | SYK (0.46) | JUNNFKB1NFKB2RELAKMT2A | |
| SCHEMBL21593637 | 0.82 | KMT2A (0.34) | MAPK8MAPK9KMT2AIRAK4LATS1 | |
| SCHEMBL21593630 | 0.81 | KMT2A (0.33) | MAPK8MAPK9KMT2AIRAK4LATS1 | |
| SCHEMBL21593590 | 0.80 | KMT2A (0.33) | KMT2ALATS1LATS2TYRO3MERTK | |
| SCHEMBL21593670 | 0.77 | AURKA (0.33) | KMT2ALATS1LATS2FLT3TYRO3 | |
| SCHEMBL23452652 | 0.76 | MAPK8 (0.48) | MAPK8MAPK9KMT2AFLT3TYRO3 | |
| SCHEMBL20330081 | 0.76 | MAPK8 (0.48) | MAPK8MAPK9KMT2AFLT3TYRO3 | |
| SCHEMBL20299422 | 0.76 | MAPK8 (0.48) | MAPK8MAPK9KMT2AFLT3TYRO3 | |
| SCHEMBL21591919 | 0.75 | BTK (0.44) | MAPK8MAPK9KMT2AIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2024-05-09 | — | — | US | disclosed |
| US-20240124492-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2024-04-18 | — | — | US | disclosed |
| CN-112236431-B | Purinone Compounds and Their Use in the Treatment of Cancer | 阿斯利康(瑞典)有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2024-01-30 | — | — | US | disclosed |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-09-05 | — | — | US | disclosed |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-09-05 | — | — | US | disclosed |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-09-05 | — | — | US | disclosed |
| EP-3807278-B1 | PURINONE DERIVATIVES AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-08-31 | — | — | EP | disclosed |
| CN-110177791-B | Amino-triazolopyridine compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2022-07-12 | — | — | CN | disclosed |
| US-11136340-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2021-10-05 | — | — | US | disclosed |
| EP-3558997-B1 | AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2021-01-27 | — | — | EP | disclosed |
| CN-112236431-A | Purinone compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2021-01-15 | — | — | CN | disclosed |
| US-20200048281-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2020-02-13 | — | — | US | disclosed |
| US-20200048281-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2020-02-13 | — | — | US | disclosed |
| US-10407446-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-09-10 | — | — | US | disclosed |
| US-10407446-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-09-10 | — | — | US | disclosed |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| WO-2018114999-A1 | AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124492-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | DCK, TYMP, DPYD | MAPK8 989/4885MAPK9 471/4885JUN 2412/4885 |
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | RECQL, PRPS1, PURB | MAPK8 1897/4885MAPK9 1136/4885JUN 2029/4885 |
| US-11136340-B2 | Amino-triazolopyridine compounds and their use in treating cancer | DCK, TYMP, DPYD | MAPK8 989/4885MAPK9 471/4885JUN 2412/4885 |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | DCK, TYMP, DPYD | MAPK8 989/4885MAPK9 471/4885JUN 2412/4885 |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | RECQL, PRPS1, PURB | MAPK8 2159/4885MAPK9 1317/4885JUN 2589/4885 |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | DCK, TYMP, DPYD | MAPK8 989/4885MAPK9 471/4885JUN 2412/4885 |
| US-20200048281-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | DCK, TYMP, DPYD | MAPK8 989/4885MAPK9 471/4885JUN 2412/4885 |
| US-10407446-B2 | Amino-triazolopyridine compounds and their use in treating cancer | DCK, TYMP, DPYD | MAPK8 989/4885MAPK9 471/4885JUN 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.